Core Laboratories NV

StockStory highlights Stryker as a cash-producing stock worth watching, while flagging Baker Hughes and Core Laboratories as facing challenges. Stryker's trailing 12-month free cash flow margin stands at 18.1%, with organic revenue growth averaging 9.2% over the past two years and EPS compounding at 12.2% annually over five years. Baker Hughes, with a free cash flow margin of 8.9%, has seen annual sales growth of 6.8% over five years and a gross margin of 22.1% that trails competitors. Core Laboratories, at a 3.5% free cash flow margin, posted muted 3.4% annual revenue growth over five years and a gross margin of 20.4%.

StockStory identified Kinder Morgan as an energy stock to watch, while naming Transocean and Core Laboratories as two that underwhelm. Kinder Morgan, with a market cap of $69.77 billion and revenue of $17.53 billion, benefits from its massive pipeline network and strong free cash flow. Transocean faces a 4.7% annual sales decline over ten years and a low free cash flow margin of 4.6%. Core Laboratories struggles with 3.4% annual sales growth over five years and a gross margin of 20.4%.

Shares of Noble Corporation, Valaris, and Core Laboratories fell sharply as Brent crude dropped below $80 per barrel for the first time since March, driven by the Iran peace deal removing a supply-disruption risk premium. Noble Corporation declined 4%, Valaris fell 4%, and Core Laboratories dropped 4.3%. The Strait of Hormuz will remain toll-free beyond the initial 60-day period, confirming the durability of the deal and further pressuring oil prices. Lower oil prices reduce revenue projections for E&P producers, which in turn cut drilling capex and reduce demand for oilfield services. Core Laboratories is down 27.9% year-to-date and trading 37.9% below its 52-week high.